Miajas, Rolando A.
HRN: 22-97-97 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/03/2023
CO-AMOXICLAV 625MG (TAB)
05/03/2023
05/10/2023
PO
625mg
BID
Exfoliative Dermatitis Superimposed With Bacterial Infection
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes